Due to increasing regulatory requirements, the need for quality study and patient safety data is critical as we work together to bring our clients’ novel treatments to patients. PRA Health Sciences is diligently working to meet our clients’ data demands through the substantial growth of our Data Monitoring Committee (DMC) services over recent years. Staffed by a global team of experts, PRA’s dedicated DMC Unit ensures our clients’ projects meet the most stringent regulatory requirements.
Explore related content and topics
Poster
A Retrospective Analysis of the Effects of Protocol Design on Completion Rates in Outpatient Clinical Trials in Subjects with Schizophrenia or Schizoaffective Disorder
Subject attrition from randomized Schizophrenia trials is a significant problem and has been found in a meta-analysis to be as high as 76%. The…
Poster
Pharmacokinetic Characteristics of Intranasal Administration of Oxycodone ARIR
Abuse of prescription opioids continues to be a serious public health concern, with as many as 12.5 million individuals aged 12 or older reporting…
Fact Sheet
The Fundamentals of Human Abuse Potential (HAP) Studies: A 7-Point Checklist
Improving the science of abuse assessment before a drug is marketed is a unified goal for the FDA and pharmaceutical industry. It is the hope that…